Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remtolumab - AbbVie

Next Previous
Drug Profile

Remtolumab - AbbVie

Alternative Names: ABT-122; Dual variable domain immunoglobulin; Dual Variable Domain–Ig™; DVD–Ig™

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antirheumatics; Immunoglobulins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Interleukin-17 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Discontinued Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 03 Sep 2019 Discontinued - Phase-I for Rheumatoid arthritis (Monotherapy) in USA (SC)
  • 03 Sep 2019 Discontinued - Phase-II for Psoriatic arthritis in USA, Latvia, Hungary, Hungary, Bulgaria, Czech Republic, France, Australia, New Zealand, Germany, Romania, Spain, Poland (SC)
  • 03 Sep 2019 Discontinued - Phase-II for Rheumatoid arthritis (Combination therapy, Treatment-experienced) in USA, Hungary, Romania, Hungary, Hungary, Australia, Canada, Czech Republic, Czech Republic, New Zealand, Poland, Bulgaria, Germany, Denmark (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top